RxDoctor Payments Data

Craig Hamasaki, MD

Internal Medicine · Aiea, HINPI 1003870478

Payments from drug & device makers

$1,318in general payments, 2019–2025

Across 69 payments — averaging $19.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$582
  • AstraZeneca$181
  • Novo Nordisk$77
  • Regeneron Healthcare Solutions, Inc.$73
  • Amarin Pharma, Inc.$66
  • GSK$47
  • plus $293 from 9 others

What the payments were for

  • Food & beverage$1,312100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,318 in reported general payments places this provider in the 70th percentile of 655 internal medicine providers in Hawaii.

See all internal medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$138,465
Medicare patients
265
Services billed
1,287

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RybelsusSemaglutide152$172,160
JanuviaSitagliptin Phosphate97$81,115
ProliaDenosumab31$54,285
OzempicSemaglutide18$20,877
EliquisApixaban23$17,993
Atorvastatin Calcium643$15,532
JanumetSitagliptin Phos/Metformin Hcl14$13,028
Rosuvastatin Calcium130$6,993
Losartan Potassium338$5,736
Raloxifene Hcl47$5,474
Ezetimibe58$4,821
Fenofibrate110$4,445
Amlodipine Besylate343$3,973
Wixela InhubFluticasone Propion/Salmeterol29$3,956
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide102$3,953

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskRybelsus, Ozempic$77$193,036170 claims
MerckJanuvia, Janumet$38$94,143111 claims
AmgenProlia$582$54,28531 claims
PfizerEliquis$38$17,99323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 655 internal medicine providers in Hawaii.

Other internal medicine in Aiea

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →